News Related to Germ Cell Tumors

iPSC-Derived NK Cell Therapies Gain Momentum with Regulatory Approvals and Expanding Clinical Pipeline

Jun 04, 2026

iPSC-derived NK cell therapies are advancing rapidly with 12+ companies developing 15+ pipeline drugs. Japan's PMDA approved an iPS cell-derived NK cell therapy for mediastinal germ cell tumors in December 2025. Key clinical milestones include Century Therapeutics' CNTY-101 continuing in a Phase I/II trial.

Liquid Biopsy Predicts Immunotherapy Response in Breast Cancer and Refines Chemotherapy Decisions in Germ Cell Tumors

Apr 30, 2026

Two studies show liquid biopsy can predict immunotherapy response in HER2-negative breast cancer and identify which patients with relapsed germ cell tumors may benefit from high-dose chemotherapy, advancing precision oncology.

Blood Tests Show Promise for Testicular Cancer Monitoring and Treatment Decisions

Mar 04, 2026

New research demonstrates blood-based biomarkers can predict testicular cancer recurrence and treatment outcomes, while separate study reveals long-term health risks vary by chemotherapy regimen in survivors.